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ABSTRACT
Background Early in the COVID- 19 pandemic, the 
National Health Service (NHS) recommended that 
appropriate patients anticoagulated with warfarin should 
be switched to direct- acting oral anticoagulants (DOACs), 
requiring less frequent blood testing. Subsequently, a 
national safety alert was issued regarding patients being 
inappropriately coprescribed two anticoagulants following 
a medication change and associated monitoring.
Objective To describe which people were switched 
from warfarin to DOACs; identify potentially unsafe 
coprescribing of anticoagulants; and assess whether 
abnormal clotting results have become more frequent 
during the pandemic.
Methods With the approval of NHS England, we 
conducted a cohort study using routine clinical data from 
24 million NHS patients in England.
Results 20 000 of 164 000 warfarin patients (12.2%) 
switched to DOACs between March and May 2020, most 
commonly to edoxaban and apixaban. Factors associated 
with switching included: older age, recent renal function 
test, higher number of recent INR tests recorded, atrial 
fibrillation diagnosis and care home residency. There was 
a sharp rise in coprescribing of warfarin and DOACs from 
typically 50–100 per month to 246 in April 2020, 0.06% 
of all people receiving a DOAC or warfarin. International 
normalised ratio (INR) testing fell by 14% to 506.8 patients 
tested per 1000 warfarin patients each month. We 
observed a very small increase in elevated INRs (n=470) 
during April compared with January (n=420).
Conclusions Increased switching of anticoagulants 
from warfarin to DOACs was observed at the outset of 
the COVID- 19 pandemic in England following national 
guidance. There was a small but substantial number of 
people coprescribed warfarin and DOACs during this 
period. Despite a national safety alert on the issue, a 
widespread rise in elevated INR test results was not found. 
Primary care has responded rapidly to changes in patient 
care during the COVID- 19 pandemic.
BACKGROUND
Anticoagulants are prescribed to people at 
risk of or for treatment of thromboembolism, 
Key questions
What is already known about this subject?
 ► Since the beginning of the COVID- 19 pandemic, the 
National Health Service (NHS) has recommended 
putting measures in place to reduce face- to- face 
contact with patients where possible to reduce 
the risk of transmission. This includes guidance to 
consider prescribing a direct- acting oral anticoagu-
lant (DOAC) instead of warfarin in suitable patients. 
However, it was not known how widespread this 
practice was, or whether it results in potentially dan-
gerous coadministration. In addition, there has one 
small report on reduced international normalised 
ratio (INR) control during the pandemic.
What does this study add?
 ► This is the first widespread study on the impact of 
the NHS England guidance. It shows that a sub-
stantial number of patients in general practice in 
England had their anticoagulant switched from war-
farin to a DOAC. It also shows that there was a small 
number of patients who potentially received both 
warfarin and a DOAC. We also showed that there 
did not appear to be a widespread reduction in INR 
control during the pandemic.
How might this impact on clinical practice?
 ► This study highlights that national prescribing guid-
ance can be implemented in primary care in England, 
both on a large scale and at a fast pace when nec-
essary to improve patient care. It also highlights the 
importance of good clinical governance processes 
when switching medications, in order to reduce the 
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which in some cases can result in stroke. Warfarin, a 
vitamin K antagonist, has been the mainstay of oral anti-
coagulant treatment for decades. A patient’s specific dose 
of warfarin is adjusted based on frequent blood tests that 
determine their international normalised ratio (INR), 
a measurement of blood clotting time. Factors such as 
changes in diet, alcohol intake, acute illness and concom-
itant medications can affect blood levels of warfarin 
and INR, requiring a temporary increase in frequency 
of testing. The quality of the anticoagulation control is 
assessed by the proportion of time in therapeutic range 
(TTR). Direct- acting oral anticoagulants’ (DOACs; rivar-
oxaban, dabigatran etexilate, apixaban and edoxaban) 
mechanism of action does not alter the INR and there-
fore people taking DOACs require less frequent drug 
safety monitoring (eg, renal function). Nationally, the 
prescribing of DOACs has increased steadily since their 
recommendation by NICE for atrial fibrillation (AF) in 
2012.1
Following the onset of the COVID- 19 pandemic, the 
National Health Service (NHS) responded to deliver 
healthcare services in a manner that minimised risk of 
virus transmission. Most patients taking the anticoagu-
lant warfarin require frequent blood tests, the INR test, 
potentially increasing their chance of exposure to SARS- 
CoV- 2. NHS England issued guidance in March 20202 
to support local NHS organisations to manage their 
anticoagulant services; this included identifying people 
suitable for switching from warfarin to DOACs. In May 
2020, NHS England wrote to Clinical Commissioning 
Groups (CCGs), the local NHS bodies responsible for 
medicines use, advising that apixaban or rivaroxaban 
should be prescribed in place of warfarin for people 
able to change,3 following a procurement exercise that 
secured additional stock at reduced prices. In October 
2020, the Medicines and Healthcare products Regula-
tory Authority (MHRA) issued a safety alert, warning 
about an increase in the number of people with substan-
tially elevated INR levels observed during the pandemic 
and also warned that of some people for whom warfarin 
was inadvertently continued after switching to DOACs4; 
however, this document gave no indication of the scale 
of these problems.
Using a retrospective cohort study design, we set out 
to: evaluate the proportion and characteristics of prior 
warfarin users who switched to DOACs and how many 
subsequently reverted; identify potentially unsafe copre-
scribing of warfarin and DOACs; and measure the 
frequency of INR testing during the pandemic for people 
taking warfarin, any changes to TTR and the extent to 
which elevated INRs were observed. This was conducted 
as a ‘proof of concept’ for the use of the new Open-
SAFELY analytics platform to rapidly understand service 
impacts during the COVID- 19 pandemic and inform 
support for primary care.
METHODS
Study design
Prescribing and testing practice was analysed by 
conducting a retrospective cohort study using data from 
English NHS general practices.
Data sources
Primary care records managed by the General Practice 
(GP) software provider TPP were assessed using Open-
SAFELY, a data analytics platform created by our team 
on behalf of NHS England to address urgent COVID- 19 
research questions (https:// opensafely. org). Open-
SAFELY provides a secure software interface allowing the 
analysis of pseudonymised primary care patient records 
from England in near real- time within the Electronic 
Health Record (EHR) vendor’s highly secure data centre, 
avoiding the need for large volumes of potentially disclo-
sive pseudonymised patient data to be transferred off- site. 
This, in addition to other technical and organisational 
controls, minimises any risk of reidentification. Similarly, 
pseudonymised datasets from other data providers are 
securely provided to the EHR vendor and linked to the 
primary care data. The dataset analysed within Open-
SAFELY is based on 24 million people currently registered 
with GP surgeries using TPP SystmOne software (40% of 
England’s population). It includes pseudonymised data 
such as coded diagnoses, medications and physiolog-
ical parameters but no free- text data. Further details on 
our information governance can be found under ethics 
approval.
Data processing
We extracted data for all people who were issued with 
a prescription or had an active repeat prescription for 
warfarin or DOACs between January 2019 and August 
2020, and the relevant dates of each prescription and 
INR test- related activity. We used warfarin, DOAC and 
INR codelists from OpenSAFELY5 6 to identify these activ-
ities, with ‘high INRs’ classified as INR of >8/≥8 (as indi-
cated) in line with thresholds relied on by the MHRA.7 We 
identified TTR using the following CTV3 codes ‘YavzQ’, 
‘42QE2’ (redundant) and ‘Xaa68’.
People switching from warfarin to DOACs following NHS 
England guidance
We identified people issued a prescription for warfarin 
(but no DOACs) between December 2019 and February 
2020 and assessed how many received at least one 
DOAC (‘switched’) in March–May 2020 or only received 
warfarin (figure 1). Of those switching, we counted how 
many later received warfarin again during this period 
(‘switched back’). Of those remaining on warfarin, we 
counted how many received an INR test, a high INR value 
or had a TTR recorded. This analysis was repeated for the 
subsequent 3- month period (warfarin March–May 2020, 
switching June–August 2020) and for the corresponding 
periods in the previous year. Descriptive tables were 
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We also assessed the overall rate of people starting new 
DOAC repeat prescriptions each month from January 
2019 to August 2020 (with ‘new’ defined as people having 
no DOAC repeat prescription ending within the previous 
3 months). We assessed how many of whom had switched 
from warfarin, defined as people having a warfarin repeat 
prescription with an end date in the previous 3 months. 
Figures were plotted on a time trend chart.
Potentially unsafe coprescribing of warfarin and a DOAC
For each month, January 2019–August 2020, patients 
were identified who: (A) were issued a prescription for 
DOAC and warfarin on the same day or (B) had a repeat 
medication initiated for both DOAC and warfarin on 
the same day (and also had at least one warfarin/DOAC 
prescription issued within the month). A repeat prescrip-
tion allows items to be issued, therefore having active 
repeats for both medications could allow both warfarin 
and a DOAC to be issued to a patient in error (however, 
prescriptions can also be issued acutely without a repeat). 
We identified whether these people had at least one of 
these cancelled the same day. Figures were plotted on a 
time trend chart.
INR tests during the COVID-19 period
Each month, INR tests and TTR values were identified 
for people on warfarin (defined as people with warfarin 
issued within the previous 3 months, and no DOAC 
issued after the latest warfarin). We plotted the rate per 
1000 warfarin patients (and for TTRs, also the rate per 
1000 INR tests and the rate per 1000 people tested) on 
time trend charts.
Factors associated with switching from warfarin to a DOAC 
during the pandemic
We investigated factors associated with switching from 
warfarin to DOAC using mixed effects logistic regres-
sion. We included the variables in table 1 as factors 
in the model. We excluded ethnicity due to ~30% 
missingness. We also planned to include the patient’s 
practice, but this was later removed to allow the model 
to converge. The population was: people aged 18–110 
years at the start of the follow- up period; registered 
with a single practice for the 6 months prior to the 
follow- up period (to ensure completeness of covariate 
data); prescribed warfarin at least once in the baseline 
period; first prescribed warfarin at least 6 months ago 
(to exclude very recent initiations); not prescribed a 
DOAC during the baseline period; and prescribed at 
least one DOAC or warfarin during the follow- up period 
(to exclude people who ceased treatment or died before 
receiving any prescription in this period). The outcome 
was the prescription of at least one DOAC during the 
follow- up period. Baseline period: 3 months prior to the 
national ‘stay at home’ order (16 December 2019–15 
March 2020); follow- up period: the following 3 months 
(16 March 2020–15 June 2020).
Software and reproducibility
Data management was performed using Python V.3.8 and 
SQL, and regression analysis using Stata V.16.1. All codes 
for the OpenSAFELY platform, and for data management 
and analyses for this study, are available for inspection and 
reuse under open licenses on GitHub (https:// github. 
com/ opensafely/ anticoagulant- switching- research). All 
codelists are available for inspection and reuse from 
https:// codelists. opensafely. org.
Patient and public involvement
Patients were not formally involved in developing this 
specific study design that was developed rapidly in the 
context of a global health emergency. We have devel-
oped a publicly available website https:// opensafely. org/ 
through which we invite any patient or member of the 
public to contact us regarding this study or the broader 
OpenSAFELY project.
Figure 1 Identification of patients. Flow chart illustrating how patients switching from warfarin to DOACs (and those switching 
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RESULTS
Patients switching from warfarin to DOACs following NHS 
England advice
A total of 164 000 people were prescribed warfarin 
between December 2019 and February 2020, of whom 
12.2% (20 000) were prescribed a DOAC between March 
and May 2020 (table 2). This was substantially higher than 
the previous year (3.5%) and the following 3 months 
(4.4%) (table 2). Of those who switched to a DOAC, 
5.8% (n=1200) also received a subsequent prescription 
for warfarin (switched back), compared with 4.1% the 
previous year (table 2). Of those remaining on warfarin, 
80.1% had at least one INR test recorded during March–
May compared with 83.7% the previous year, 38.6% had 
at least one recorded INR TTR (37.9% the previous 
year), and 0.5% had a high INR (≥8) result (0.4% the 
previous year; table 2). During March–May 2020, edox-
aban and apixaban were the most commonly selected 
DOACs among those who were switched (38.1% and 
33.5%, respectively; table 3). During June–August 2020, 
Table 1 Variables used to assess factors associated with switching (present on the first day of the follow- up period unless 
otherwise stated)
Factor Detailed information on coding Codelist (where applicable)
Age group <65, 65–74 and 75+   
Indices of Multiple Deprivation (IMD) Deciles based on residential postcode Supplied by TPP.
Sustainability and transformation partnership 
(STP) membership
STP of current registered practice – modelled as a 
random effect
STP are NHS administrative regions made up of 
one or more CCGs.
Linkage to national STPs carried out by TPP.
Care/nursing home residence status Yes/no Classification supplied by TPP based on patient’s 
residential address at 1 February 2020 linked to 
CQC care home register.
Diagnosis of AF Yes/no; any time prior to follow- up period https://codelists.opensafely.org/codelist/
opensafely/atrial-fibrillation/2020-07-09/
Renal function Latest estimated Glomerular Filtration Rate (eGFR 
function) (<30, 30–59 and ≥60) in the 12 months to 
the end of the baseline period (or ‘no evidence’ for 
those with no creatinine recorded in this period).
eGFR calculated from creatinine records.
Creatinine clearance is recommended renal 
function assessment for tailoring DOAC doses 
for individual people. Automated calculation of 
Creatinine Clearance (CrCl) is not yet available 
in OpenSAFELY, and eGFR is used as pragmatic 
alternative.
Recent renal function test Yes/no; within last 4 months and up to the end of the 
study period (this conservatively allows tests slightly 
outside of the recommended 3- month period, and any 
time during the switching period).
  Creatinine test or:
 ►  ‘451’. Renal function test.
 ►  ‘XacUK’ eGFR using creatinine (calculated 
using Chronic Kidney Disease- Epidemiology 
Collaboration (CKD- EPI) per 1.73 square 
metres.
Number of INR tests 0, 1–3, 4–6 or 7+ tests during the baseline period https://codelists.opensafely.org/codelist/
opensafely/international-normalised-ratio-
inr/2020-10-22
Length of time on warfarin*  ► <2 years (since 16 March 2018).
 ► 2–≤6 years (since June 2014, date of latest 
National Institute of Health and Care Excellence 
(NICE) AF guidance).22
 ► 6–<8 years (since March 2012, date of first NICE 
Technology Appraisal for a DOAC for AF).23
 ► ≥8 years.
https://codelists.opensafely.org/codelist/
opensafely/warfarin/2020-10-05/
Previously prescribed DOACs* Yes/no; any time prior to the baseline period. https://codelists.opensafely.org/codelist/
opensafely/direct-acting-oral-anticoagulants-
doac/2020-10-05/
Explicitly recorded contraindicaton to DOAC Yes/no; any time prior to the follow- up period. https://codelists.opensafely.org/codelist/
opensafely/explicit-contraindication-to-doacs-
direct-acting-anticoagulants/2020-10-19/
*The earliest actual date of an event may be missing due to incomplete patient records (eg, lost in transfer between practices), but the 
earliest recorded date can be used as an approximation.
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apixaban had increased to 40.3%, with edoxaban drop-
ping to 33.4% (table 3).
The initiation of repeat prescriptions for DOACs to 
new patients increased ~1.5- fold during March and April 
2020 and subsequently dropped slightly below normal 
levels (figure 2). Much of this increase was attributable to 
people switching from warfarin (40.3% in March 57.5% 
in April), compared with the normal rate of ~15% per 
month (figure 2).
Potentially unsafe coprescribing of warfarin and a DOAC
Prior to the pandemic period, typically 50–100 people 
per month had both warfarin and a DOAC issued on the 
same day, rising sharply to 246 in April 2020 (0.06% of all 
people receiving a DOAC or warfarin) before declining 
gradually to almost baseline by August 2020 (figure 3A). 
Only a small proportion of these patients had at least one 
of their coprescriptions cancelled on the same day (ie, 
prescription end date equal to start date). Prior to the 
pandemic, 60–110 patients per month had both warfarin 
and a DOAC repeat prescription initiated on the same 
day (figure 3B). This figure reached a peak of ~170 in 
April and declined rapidly to near- normal levels from 
May 2020. However, this rise was compensated by an 
increase in the number of repeat prescriptions that were 
cancelled the same day (usually warfarin).
INR tests during the COVID-19 period
Of 164 000 people on warfarin prior to March 2020, 
80.1% had an INR test recorded and 35% had a TTR 
recorded between March and May 2020 (table 2). The 
number of warfarin patients tested each month was 
Table 2 Warfarin patients switching to DOACs or remaining on warfarin
Patient count, thousands (percentage)
Period March–May June–August
Year 2020 2019 2020 2019
Baseline warfarin patients** 164 000 195 000 143 200 185 900
Switched 20 000 (12.2) 6900 (3.5) 6300 (4.4) 5900 (3.2)
Continued warfarin 136 100 (83.0) 177 300 (90.9) 128 200 (89.5) 169 900 (91.4)
No anticoagulants† 7900 (4.8) 10 800 (5.6) 8700 (6.1) 10 100 (5.4)
Switched back
(% of switchers)
1200 (5.8) 300 (4.1) 300 (4.7) 300 (4.4)
At least one INR
(% of continued)
109 100 (80.1) 148 400 (83.7) 101 100 (78.8) 140 000 (82.4)
At least one TTR
(% of continued)
52 600 (38.6) 67 200 (37.9) 50 300 (39.2) 66 500 (39.1)
High INR (≥8)
(% of continued)
700 (0.5) 700 (0.4) 400 (0.3) 600 (0.3)
Number and percentage of warfarin patients who continued on warfarin, received a DOAC (‘switched’) or had no anticoagulants, during 
March–May 2020 compared with 2019 and similarly for June–August. Also showing the percentage of those switching to a DOAC who later 
received warfarin ‘switched back’ (within the same 3- month period); and the percentage of those remaining on warfarin who had at least one 
INR test, INR TTR or high INR (≥8) recorded. Patient counts are rounded to the nearest 100.
*Baseline warfarin patients for each period were those issued warfarin at least once (but no DOACs) in the 3 months immediately prior to the 
period shown.
†Those with no anticoagulants (referring to warfarin and DOACs only) in the follow- up period may have discontinued anticoagulant treatment, 
moved to a non- TPP practice, died or simply had a long period without a new prescription from their GP (eg, due to a hospital stay or longer 
than usual prescription duration).
DOACs, direct- acting oral anticoagulants; INR, international normalised ratio; TTR, time in therapeutic range.
Table 3 Types of DOAC selected
Period Year
Apixaban Edoxaban Rivaroxaban Dabigatran etexilate
TotalPatient count % Patient count % Patient count % Patient count %
March–May 2020 6700 33.5 7620 38.1 5550 27.8 120 0.6 19 990
2019 3510 51.1 1040 15.2 2190 31.9 120 1.8 6860
June–August 2020 2550 40.3 2110 33.4 1620 25.6 40 0.6 6320
2019 2900 49.5 1110 18.9 1760 30 90 1.6 5860
Number and percentage of warfarin patients switched to each of the four types of DOAC between March and May 2020 compared with 
2019, and similarly for June–August, for people who were prescribed warfarin during the previous 3- month period. Patient counts are 
rounded to the nearest 10. Percentages may not add to exactly 100 due to rounding.
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approximately constant prior to the pandemic (589 per 
1000 eligible patients per month, January 2019–March 
2020) but with a small reduction during the pandemic 
(figure 4A). The monthly testing rate reduced by 14%, 
to 506.8 (April–August 2020), a reduction of 82.4 per 
1000 patients being tested per month (14.0% reduc-
tion). The number of TTRs recorded followed a similar 
pattern (figure 4B), and where TTR was recorded, the 
mean value for those who were still on warfarin remained 
relatively constant (figure 4C). Figure 4D,E illustrate the 
rate of high INRs per 1000 warfarin patients, per 1000 
INR tests and per 1000 patients tested. A small peak is 
observed in April, but the absolute number of high INR 
results (≥8) was 470, only slightly higher than January’s 
figure of 420 (online supplemental table S1).
Factors associated with switching from warfarin to a DOAC 
during the pandemic
A total of 149 243 people were included in this analysis 
(online supplemental table S3) and our logistic regres-
sion model results are presented in table 4. People who 
had reduced renal function were less likely to switch from 
warfarin to DOAC compared with those with eGFR ≥60 
(eGFR <30: OR 0.51, 95% CI 0.46 to 0.57; eGFR 30–59: OR 
0.92, 95% CI 0.88 to 0.96). Those with no eGFR in the last 
12 months but who had had a renal function test recorded 
in the last 4 months were more likely to switch (OR 2.11, 
95% CI 2.02 to 2.21), while those with no eGFR or recent 
renal function test were less likely to switch (0.40, 95% CI 
0.38 to 0.42). People with multiple recent INR tests were 
more likely to switch (over seven vs none recorded, OR 
1.88, 95% CI 1.77 to 1.99); older people (over 75 vs under 
65, OR 1.89, 95% CI 1.77 to 1.99); people living in a care 
home (OR 1.32, 95% CI 1.15 to 1.51); and people with a 
diagnosis of AF (OR 1.95, 95% CI 1.87 to 2.03). People 
with a recorded contraindication for a DOAC were less 
likely to be switched (OR 0.37, 95% CI 0.26 to 0.52). We 
also found that Sustainability and Transformation Part-
nership (STP) membership, when modelled as a random 
effect, was a significant driver of variation (p<0.0001).
Figure 2 Patients newly initiated on DOAC repeats. Number 
of people having a new DOAC repeat prescription initiated 
per month (where the patient had no prior DOAC repeat 
ending within the previous 3 months), indicating whether 
or not patients had previously had a repeat prescription for 
warfarin (ending same month or within previous 3 months). 
DOAC, direct- acting oral anticoagulants.
Figure 3 Patients coprescribed warfarin and a DOAC. Number of patients having (A) both warfarin and a DOAC prescription 
issued on the same day, also indicating how many patients for whom one of those prescriptions was cancelled the same 
day (ie, its end date was equal to its start date); (B) both warfarin and a DOAC repeat prescriptions initiated on the same day 
(restricted to patients who also had at least one warfarin or DOAC prescription issued in the given month), also indicating how 
many patients for whom one of those repeat prescriptions was cancelled the same day (ie, its end date was equal to its start 
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DISCUSSION
Summary
We observed a substantial increase in people switching 
from warfarin to a DOAC after NHS England advice to 
do so during the COVID- 19 pandemic. We were able to 
identify in the data that a small but substantial number 
of people (n=246, 0.06%) simultaneously prescribed 
warfarin and a DOAC in April 2020 and were potentially 
at risk of serious adverse effects. Overall, the rate of INR 
testing for those on warfarin dropped by 14%, although 
we observed no substantial change in the proportion of 
INR tests that reported a clotting time outside the desired 
range. Factors associated with switching from warfarin to 
DOACs included older age, higher number of recent 
INR tests, diagnosis of AF, normal renal function and 
care home residency.
Strengths and weaknesses
The key strength of this study is the scale, timeliness and 
completeness of the underlying data. The OpenSAFELY 
platform runs analyses across the full, raw, single- event- 
level medical records of all patients at 40% of all GP 
practices in England, including all tests, treatments, diag-
nostic events and other salient clinical and demographic 
information. We also recognise some limitations. We 
assessed the number of prescriptions issued or initiated 
on repeat prescriptions. We cannot currently access 
information on which medications were dispensed. An 
individual appearing to receive warfarin and a DOAC 
may therefore not receive, or take, both medications: for 
example, a doctor might notice the coprescribing some 
time after the consultation and cancel the prescription, 
or a pharmacist may decline to dispense both medica-
tions for safety reasons. Finally, a patient may be informed 
not to take the medicine by their healthcare professional 
even if they received a dispensed medicine. Nonetheless, 
this does not diminish the finding that coprescribing of 
warfarin and DOACs occurs and that incidence increased 
substantially during COVID- 19 to over 200 people in 1 
month. Another limitation relates to missing INR data: 
people in England often have their warfarin managed 
by an ‘anticoagulation clinic’ in a community service, 
hospital outpatient department or neighbouring general 
practice with specialist expertise; these clinics typically use 
bespoke software to record all relevant results related to 
INR, which may not be transferred in structured data into 
GP records but would be visible to clinicians delivering 
Figure 4 INR tests and recorded TTRs in warfarin patients. (A) Number of patients having an INR test, and the total number 
of INR tests carried out, per thousand warfarin patients. (B) Number of patients having a TTR recorded, and the total number 
of TTRs, per thousand warfarin patients. (C) Mean TTR value across warfarin patients tested. (D) Monthly rate of elevated INRs 
(as >8 and ≥8) recorded in warfarin patients per thousand warfarin patients and thousand patients having an INR test. INR, 
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direct care for a patient; this could explain the apparent 
absence of INR tests for some people but not negatively 
impact clinical care. Our regression analysis could not 
capture all possible causes of confounding; in particular. 
the patient’s practice was excluded to allow the model to 
converge, and this would be expected to have a strong 
influence on anticoagulant prescribing.
Findings in context
A recent systematic review of healthcare utilisation during 
the pandemic found that utilisation reduced by approxi-
mately one- third during the pandemic,8 but we are not aware 
of any published studies assessing switching of anticoagulant 
therapy during the pandemic or implementation of NHS 
England anticoagulation guidance. We found that edoxaban 
and apixaban were favoured DOACs when switching from 
warfarin, not wholly in line with NHS England advice from 
May 2020,3 which recommends apixaban and rivaroxaban. 
In October, NICE published draft guidance on AF recom-
mending apixaban and dabigatran; however, we found 
dabigatran was prescribed in a very small proportion of 
switches.9 In England, general practitioners have autonomy 
in the selection of treatments they prescribe but are obliged 
to consider a wide number of factors that may influence 
choice of DOACs.10 Our previous research has shown NHS 
England guidance advising GPs to stop prescribing certain 
medicines that did not cause an immediate noticeable 
Table 4 Factors associated with switching from warfarin to a DOAC during the pandemic
Univariable logistic regression Mixed effects logistic regression*
OR 95% CI OR 95% CI
Age (years) Under 65 Ref Ref
65–74 2.05 1.93 to 2.17 1.50 1.41 to 1.60
75 and over 2.87 2.72 to 3.03 1.89 1.78 to 2.01
Index of multiple deprivation Quintile 5 (least 
deprived) Ref Ref
Quintile 4 1.13 1.07 to 1.19 1.07 1.01 to 1.13
Quintile 3 1.21 1.15 to 1.27 1.07 1.02 to 1.13
Quintile 2 1.20 1.14 to 1.26 1.05 1.00 to 1.11
Quintile 1 (most 
deprived)
1.20 1.14 to 1.27 1.03 0.97 to 1.08
Care home No Ref Ref
Yes 1.47 1.29 to 1.68 1.32 1.15 to 1.51
Atrial fibrillation No Ref Ref
Yes 2.49 2.39 to 2.58 1.95 1.87 to 2.03
eGFR ≥60 Ref Ref
Not measured 0.38 0.36 to 0.40 0.40 0.38 to 0.42
30–59 1.12 1.08 to 1.17 0.92 0.88 to 0.96
<30 0.63 0.57 to 0.70 0.51 0.46 to 0.57
Other RFT 2.20 2.10 to 2.30 2.11 2.02 to 2.21
Number of recent INR tests 0 Ref Ref
1–3 1.50 1.42 to 1.58 1.35 1.28 to 1.42
4–6 1.96 1.85 to 2.06 1.75 1.66 to 1.85
7+ 1.99 1.88 to 2.11 1.88 1.77 to 1.99
Length of warfarin prescription (years) <2 Ref Ref
2–≤6 1.69 1.54 to 1.85 1.26 1.14 to 1.38
6–<8 1.89 1.72 to 2.07 1.31 1.19 to 1.44
≥8 1.58 1.44 to 1.73 1.14 1.04 to 1.26
Previous DOAC prescription No Ref Ref
Yes 0.65 0.60 to 0.70 0.65 0.60 to 0.70
DOAC contraindication No Ref Ref
Yes 0.41 0.30 to 0.58 0.37 0.26 to 0.52
Patient counts are reported in online supplemental table S3.
*Adjusted for the variables in the table STP membership as a random effect.
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change in prescribing patterns,11 and CCG membership has 
a strong association with GP prescribing choices.12–15 Our 
study shows evidence of switching after the guidance and 
although we were not able to directly assess CCG member-
ship, our study did find that STPs, an administrative region 
made up of one or more CCGs, were a significant driver of 
variation. The MHRA safety alert on anticoagulation identi-
fied a ‘small number of patients’ coprescribed warfarin and 
a DOAC but provided no further information on the scale of 
the problem. One Swiss hospital found 0.8% of its patients 
on anticoagulant therapy (121/15812) were coprescribed 
two anticoagulants in a single year.16 However, 88.7% of these 
cases involved coprescription of DOACs and low- molecular 
weight heparins, not included in our study. As regards INR 
tests, the MHRA reports appears to have been triggered 
by a root cause analysis from a single centre in London,17 
reporting that between 1 March and 17 April 2020, 0.9% 
(30/3214) of INRs were high (>8.0) compared with 0.1% 
(6/4079) the previous year. Analysing the full records of 
40% of patients in England, we found only a small peak in 
high INRs and with no obvious change in the mean TTR 
recorded for those still on warfarin.
Policy implications for research and practice
The COVID- 19 pandemic has brought new challenges 
for the NHS to deliver safe and effective routine care. 
NHS England issued anticoagulant guidance at the peak 
of the pandemic and a substantial number of people 
were switched in line with this guidance. This study using 
OpenSAFELY demonstrates it is possible to use routinely 
collected raw EHR data on a specific clinical area to 
support evaluation of national guidance and safety alerts 
during the COVID- 19 pandemic. There is a need for high 
quality applied practical research to support healthcare 
organisations’ responses to the pandemic; OpenSAFELY 
can be used by NHS England, the MHRA and others such 
as NICE to rapidly assess in near- real time the impact of 
policy and clinical guidance as well as informing future 
versions of guidance. Specific areas of focus for anticoagu-
lants during COVID- 19 could include: identifying people 
eligible for switching who have not switched yet; assessing 
the scale of clinical work needed; evaluating complete-
ness of uptake; prioritising risk groups; understanding 
causes of coprescription of warfarin and DOACs; eval-
uating variation in organisations response to new guid-
ance14; and better understanding the factors identified 
by MHRA as being associated with elevated INRs such as 
coprescribing of antibiotics.4
Summary
We observed increased switching of anticoagulants 
from warfarin to DOACs at the outset of the COVID- 19 
pandemic in England. We did not find a widespread rise 
in elevated INR test results that may be reassuring after 
a recent MHRA safety alert, although we did observe a 
small but substantial number of people who were copre-
scribed warfarin and DOACs.
Author affiliations
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of 
Oxford, Oxford, UK
2TPP, Leeds, UK
3Department of Non- communicable Disease Epidemiology, London School of 
Hygiene & Tropical Medicine, London, UK
4Department of Medical Statistics, London School of Hygiene & Tropical Medicine, 
London, UK
5Department of Infectious Disease Epidemiology, London School of Hygiene & 
Tropical Medicine, London, UK
6Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Acknowledgements We are very grateful for all the support received from the 
TPP Technical Operations team throughout this work and for generous assistance 
from the information governance and database teams at National Health Service 
(NHS) England/NHSX.
Contributors Conceptualisation: HJC, BM, AJW and RC; data curation: HJC, AJW, 
SB, GH, PI, CB, DE and SD; formal analysis: HJC and AJW; funding acquisition: 
FH, LS and BG; investigation: HJC, BM, AJW, RC and BG; methodology: HJC, BM, 
AJW and RC; project administration: HJC, BM and RC; resources: HJC, SB, DE, FH 
and BG; software: HJC, AJW, RC, SB, GH, PI, DE, JC, SD and SH; supervision: BG; 
visualisation: HJC and AJW; writing – original draft: HJC, BM, AJW, RC, AM, AYSW 
and BG; writing – review and editing: all authors; BG is guarantor.
Funding The OpenSAFELY platform is supported by funding from UKRI/MRC, 
Wellcome trust and funding from the National Core Studies programme. TPP 
provided technical expertise and infrastructure within their data centre pro bono in 
the context of a national emergency.
Disclaimer Funders had no role in the study design, collection, analysis and 
interpretation of data; in the writing of the report; and in the decision to submit 
the article for publication. The views expressed are those of the authors and 
not necessarily those of the NIHR, NHS England, Public Health England or the 
Department of Health and Social Care.
Competing interests All authors have completed the ICMJE uniform disclosure 
form at www. icmje. org/ coi_ disclosure. pdf and declare the following: over the 
past 5 years, BG has received research funding from the Laura and John Arnold 
Foundation, the NHS National Institute for Health Research (NIHR), the NIHR 
School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, 
the Mohn- Westlake Foundation, NIHR Applied Research Collaboration Oxford and 
Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data 
Research UK (HDRUK), the Health Foundation and the World Health Organisation; 
he also receives personal income from speaking and writing for lay audiences 
on the misuse of science. LS reports institutional grants from Wellcome, Medical 
Research Council (MRC), NIHR andUK Research and Innovation (UKRI). LT reports 
grants from Wellcome and MRC. KB holds a Sir Henry Dale fellowship jointly 
funded by Wellcome and the Royal Society (107731/Z/15/Z). RME holds grants 
from NIHR, MRC and HDRUK. RM holds a Sir Henry Wellcome Fellowship funded by 
the Wellcome Trust (201375/Z/16/Z). HF holds a UKRI fellowship. IJD has received 
unrestricted research grants and holds shares in GlaxoSmithKline.
Patient consent for publication Not applicable.
Ethics approval NHS England is the data controller; TPP are the data processors, 
and the key researchers on OpenSAFELY are acting on behalf of NHS England. This 
implementation of OpenSAFELY is hosted within the TPP environment, which is 
accredited to the ISO 27001 information security standard and (is) NHS IG Toolkit 
compliant;18 19 patient data have been pseudonymised for analysis and linkage 
using industry standard cryptographic hashing techniques; all pseudonymised 
datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the 
platform is via a virtual private network (VPN) connection, restricted to a small 
group of researchers; the researchers hold contracts with NHS England and only 
access the platform to initiate database queries and statistical models; all database 
activity is logged; only aggregate statistical outputs leave the platform environment 
following best practice for anonymisation of results such as statistical disclosure 
control for low cell counts.20 The OpenSAFELY research platform adheres to the 
data protection principles of the UK Data Protection Act 2018 and the EU General 
Data Protection Regulation 2016. In March 2020, the Secretary of State for Health 
and Social Care used powers under the UK Health Service (Control of Patient 
Information) Regulations 2002 to require organisations to process confidential 
patient information for the purposes of protecting public health, providing 






ber 1, 2021 at T














10  , et al. Open Heart 2021;8:e001784. doi:10.1136/openhrt-2021-001784
outbreak and incidents of exposure; this sets aside the requirement for patient 
consent.21 Taken together, these provide the legal bases to link patient datasets 
on the OpenSAFELY platform. GP practices, from which the primary care data are 
obtained, are required to share relevant health information to support the public 
health response to the pandemic and have been informed of the OpenSAFELY 
analytics platform. This study was approved by the Health Research Authority (REC 
reference 20/LO/0651) and by the London School of Hygiene & Tropical Medicine 
SHTM Ethics Board (reference 21863).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access 
repository.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Helen J Curtis http:// orcid. org/ 0000- 0003- 3429- 9576
Brian MacKenna http:// orcid. org/ 0000- 0002- 3786- 9063
Alex J Walker http:// orcid. org/ 0000- 0003- 4932- 6135
Richard Croker http:// orcid. org/ 0000- 0002- 8114- 9186
Amir Mehrkar http:// orcid. org/ 0000- 0002- 2098- 1278
Caroline Morton http:// orcid. org/ 0000- 0003- 0783- 0042
Seb Bacon http:// orcid. org/ 0000- 0002- 6354- 3454
Chris Bates http:// orcid. org/ 0000- 0003- 0113- 2593
David Evans http:// orcid. org/ 0000- 0002- 1100- 079X
Jonathan Cockburn http:// orcid. org/ 0000- 0002- 4681- 4873
Krishnan Bhaskaran http:// orcid. org/ 0000- 0001- 5364- 8757
Anna Schultze http:// orcid. org/ 0000- 0002- 1637- 837X
Christopher T Rentsch http:// orcid. org/ 0000- 0002- 1408- 7907
William Hulme http:// orcid. org/ 0000- 0002- 9162- 4999
Laurie Tomlinson http:// orcid. org/ 0000- 0001- 8848- 9493
Rosalind M Eggo http:// orcid. org/ 0000- 0002- 0362- 6717
Angel Yun Wong http:// orcid. org/ 0000- 0002- 8618- 7333
Harriet Forbes http:// orcid. org/ 0000- 0001- 6888- 2212
Ian Douglas http:// orcid. org/ 0000- 0002- 8970- 1406
Liam Smeeth http:// orcid. org/ 0000- 0002- 9168- 6022
Ben Goldacre http:// orcid. org/ 0000- 0002- 5127- 4728
REFERENCES
 1 The DataLab. Direct oral anticoagulants (DOACs) measure. 
OpenPrescribing. Available: https:// openprescribing. net/ measure/ 
doacs/ national/ england/ [Accessed 30 Sep 2020].
 2 NHS England. Clinical guide for the management of anticoagulant 
services during the coronavirus pandemic, 2020. Available: https:// 
web. archive. org/ web/ 20200513044959/ https:// www. england. nhs. uk/ 
coronavirus/ wp- content/ uploads/ sites/ 52/ 2020/ 03/ C0077- Specialty- 
guide_ Anticoagulant- services- and- coronavirus- v1- 31- March. pdf 
[Accessed 20 Jul 2020].
 3 NHS England. Supply of additional direct oral anticoagulants 
(DOACs) during COVID- 19, 2020. Available: https://www. worcslmc. 
co. uk/ cache/ downloads/ C0517- DOAC- briefing- for- CCGs_ 27- May. 
pdf
 4 Warfarin and other anticoagulants – monitoring of patients during the 
COVID- 19 pandemic. Available: https://www. gov. uk/ government/ 
publications/ warfarin- and- other- anticoagulants- monitoring- of- 
patients- during- the- covid- 19- pandemic/ warfarin- and- other- 
anticoagulants- monitoring- of- patients- during- the- covid- 19- 
pandemic [Accessed 16 Oct 2020].
 5 Curtis HJ, MacKenna B, Croker R. OpenSAFELY Codelists: 
direct acting oral anticoagulants (DOAC), 2020. Available: https:// 
codelists. opensafely. org/ codelist/ opensafely/ direct- acting- oral- 
anticoagulants- doac/ 2020- 10- 05/ [Accessed 28 Oct 2020].
 6 Curtis HJ, MacKenna B, Croker R. OpenSAFELY Codelists: warfarin, 
2020. Available: https:// codelists. opensafely. org/ codelist/ opensafely/ 
warfarin/ 2020- 10- 05/ [Accessed 28 Oct 2020].
 7 OpenSAFELY Codelists: international normalised ratio (Inr). Available: 
https:// codelists. opensafely. org/ codelist/ opensafely/ international- 
normalised- ratio- inr/ 2020- 10- 22/ [Accessed 3 Nov 2020].
 8 Moynihan R, Sanders S, Michaleff ZA. Pandemic impacts on 
healthcare utilisation: a systematic review. medRxiv 2020.
 9 Consultation | atrial fibrillation: management | guidance. NICE. 
Available: https://www. nice. org. uk/ guidance/ indevelopment/ gid- 
ng10100/ consultation/ html- content-2 [Accessed 28 Oct 2020].
 10 NHS England. Standard general medical services contract. Available: 
https://www. england. nhs. uk/ gp/ investment/ gp- contract/
 11 Walker AJ, Bacon S, Curtis H, et al. Six months on: NHS England 
needs to focus on Dissemination, implementation and audit of its 
low- priority initiative. J R Soc Med 2019;112:4- 5.
 12 Walker AJ, Curtis HJ, Bacon S, et al. Trends, geographical 
variation and factors associated with prescribing of gluten- free 
foods in English primary care: a cross- sectional study. BMJ Open 
2018;8:e021312.
 13 Croker R, Walker AJ, Goldacre B. Why did some practices not 
implement new antibiotic prescribing guidelines on urinary tract 
infection? a cohort study and survey in NHS England primary care. J 
Antimicrob Chemother 2019;74:1125–32.
 14 Walker AJ, Pretis F, Powell- Smith A, et al. Variation in responsiveness 
to warranted behaviour change among NHS clinicians: novel 
implementation of change detection methods in longitudinal 
prescribing data. BMJ 2019;367:l5205.
 15 MacKenna B, Curtis HJ, Walker AJ, et al. Trends and variation in 
unsafe prescribing of methotrexate: a cohort study in English NHS 
primary care. Br J Gen Pract 2020;70:e481- e488.
 16 Rahmanzade R, Cabrera Diaz F, Zaugg C, et al. Therapeutic 
duplication of anticoagulants: a retrospective study of frequency and 
consequences in a tertiary referral hospital. Thromb J 2020;18:14.
 17 Speed V, Patel RK, Byrne R, et al. A perfect storm: root cause 
analysis of supra- therapeutic anticoagulation with vitamin 
K antagonists during the COVID- 19 pandemic. Thromb Res 
2020;192:73–4.
 18 Beta – data security standards. NHS digital. Available: https:// digital. 
nhs. uk/ about- nhs- digital/ our- work/ nhs- digital- data- and- technology- 
standards/ framework/ beta- data- security- standards [Accessed 30 
Apr 2020].
 19 Data security and protection toolkit. NHS digital. Available: https:// 
digital. nhs. uk/ data- and- information/ looking- after- information/ data- 
security- and- information- governance/ data- security- and- protection- 
toolkit [Accessed 30 Apr 2020].
 20 ISB1523: Anonymisation standard for publishing health and social 
care data. NHS digital. Available: https:// digital. nhs. uk/ data- and- 
information/ information- standards/ information- standards- and- data- 
collections- including- extractions/ publications- and- notifications/ 
standards- and- collections/ isb1523- anonymisation- standard- for- 
publishing- health- and- social- care- data [Accessed 30 Apr 2020].
 21 Secretary of State for Health and Social Care - UK Government. 
Coronavirus (COVID- 19): notification to organisations to share 
information, 2020. Available: https:// web. archive. org/ web/ 
20200421171727/ https:// www. gov. uk/ government/ publications/ 
coronavirus- covid- 19- notification- of- data- controllers- to- share- 
information
 22 NICE. Overview | atrial fibrillation: management | guidance. Available: 
https://www. nice. org. uk/ guidance/ cg180 [Accessed 30 Sep 2020].
 23 NICE. Nice key therapeutic topic: anticoagulants, including direct- 
acting oral anticoagulants (DOACs), 2016. Available: https://www. 
nice. org. uk/ advice/ ktt16/ resources/ anticoagulants- including- 
directacting- oral- anticoagulants- doacs- pdf- 58757956094149 






ber 1, 2021 at T







eart: first published as 10.1136/openhrt-2021-001784 on 16 N
ovem
ber 2021. D
ow
nloaded from
 
